(Q38232368)

31 August 2017

title

VEGF-targeted cancer therapeutics-paradoxical effects in endocrine organs (English)

1 reference

31 August 2017

Yihai Cao

1

1 reference

31 August 2017

publication date

22 July 2014

1 reference

Nature Reviews Endocrinology

31 August 2017

published in

1 reference

31 August 2017

volume

10

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

530-539

1 reference

The biology of VEGF and its receptors

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Properties of Two VEGF Receptors, Flt-1 and KDR, in Signal Transductiona

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Positive and negative modulation of angiogenesis by VEGFR1 ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Safety of bevacizumab in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Targeted inhibition of VEGF receptor 2: an update on ramucirumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Off-tumor target--beneficial site for antiangiogenic cancer therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Islet vasculature as a regulator of endocrine pancreas function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Glomerular permeability. I. Ferritin transfer across the normal glomerular capillary wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Inappropriate heat dissipation ignites brown fat thermogenesis in mice with a mutant thyroid hormone receptor α1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The barrier within: endothelial transport of hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Connective tissue growth factor acts within both endothelial cells and beta cells to promote proliferation of developing beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Rings of membrane sterols surround the openings of vesicles and fenestrae, in capillary endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Vascular endothelial growth factor induces endothelial fenestrations in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Perlecan and tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Paraneoplastic symptoms: cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Lymphangiogenesis and cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Molecular regulation of angiogenesis and lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

A randomized trial of bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Immunotherapy of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

High-dose chemotherapy regimens for solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Changing end points in breast-cancer drug approval--the Avastin story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Bevacizumab added to neoadjuvant chemotherapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Reduction in thyroid perfusion after bevacizumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Targeted therapies for renal cell carcinoma: review of adverse event management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Effect of sunitinib on growth and function of FRTL-5 thyroid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Thyroid hormone inactivation in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

How does sunitinib cause hypothyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Cachexia in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

21 January 2018

Cancer without disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Vascular endothelial growth factor C induces angiogenesis in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Regulation of extravascular coagulation by microvascular permeability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Tumor angiogenesis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Norrin/Frizzled4 signaling in retinal vascular development and blood brain barrier plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Comparative Evaluation of FGF-2–, VEGF-A–, and VEGF-C–Induced Angiogenesis, Lymphangiogenesis, Vascular Fenestrations, and Permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Measurement of phosphorylated extracellular signal-regulated kinase 1 and 2 in an undergraduate teaching laboratory with ALPHAscreen technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The ultrastructure of the capillary fenestrae in the adrenal medulla of the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Vascular permeability to proteins and peptides in the mouse pineal gland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Morphological changes in the hypothalamic arcuate nucleus and median eminence in the golden hamster during the neonatal period

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Small GTP-Binding Protein Rac Is an Essential Mediator of Vascular Endothelial Growth Factor-Induced Endothelial Fenestrations and Vascular Permeability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Distinct capillary density and progression promoted by vascular endothelial growth factor-A homodimers and heterodimers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

The VEGF splice variants: properties, receptors, and usage for the treatment of ischemic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Sinusoidal dilatation of the liver as a paraneoplastic manifestation of renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

A Novel Tyrosine-Kinase Selective Inhibitor, Sunitinib, Induces Transient Hypothyroidism by Blocking Iodine Uptake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

A case of acute adrenal insufficiency unmasked during sunitinib treatment for metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2014.114

Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction

31 March 2020

1 reference

12 December 2020

Forty-year journey of angiogenesis translational research

1 reference

12 December 2020

Stauffer syndrome, paraneoplastic hepatic dysfunction syndrome associated with renal cell carcinoma (author's transl)

1 reference

12 December 2020

Structural aspects of the permeability of the microvascular endothelium

1 reference

12 December 2020

Paraneoplastic syndromes in lung cancer

1 reference

12 December 2020

Erythropoietin deficiency decreases vascular stability in mice.

1 reference

12 December 2020

The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing

1 reference

12 December 2020

Feasibility and tolerability of bevacizumab in children with primary CNS tumors

1 reference

12 December 2020

Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer.

1 reference

12 December 2020

Pseudoislet vascularization. Induction of diaphragm-fenestrated endothelia from the hepatic sinusoids

1 reference

12 December 2020

Optimizing the delivery of cancer drugs that block angiogenesis

1 reference

12 December 2020

Bevacizumab: more fatal adverse effects

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2014.114

1 reference

31 August 2017

1 reference